{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:05:55Z","timestamp":1789736755452,"version":"4.0.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100020410","name":"T\u00fcrkiye Sa\u011fl\u0131k Enstit\u00fcleri Ba\u015fkanl\u0131\u011f\u0131","doi-asserted-by":"publisher","award":["2024-A4-01-38934"],"award-info":[{"award-number":["2024-A4-01-38934"]}],"id":[{"id":"10.13039\/100020410","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004045","name":"Karadeniz Teknik \u00dcniversitesi","doi-asserted-by":"publisher","award":["TSA-2024-11015"],"award-info":[{"award-number":["TSA-2024-11015"]}],"id":[{"id":"10.13039\/501100004045","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004410","name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ft\u0131rma Kurumu","doi-asserted-by":"publisher","award":["1649B032404194"],"award-info":[{"award-number":["1649B032404194"]}],"id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12760-4","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T12:26:05Z","timestamp":1789734365000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["NHSL3 knockout modulates sorafenib response, growth, and motility in hepatocellular carcinoma cell models"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6714-3343","authenticated-orcid":false,"given":"G\u00f6khan","family":"Y\u0131ld\u0131z","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soner","family":"Karabulut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuba","family":"Din\u00e7er","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"12760_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"12760_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41392-024-02075-w","volume":"10","author":"J Zheng","year":"2025","unstructured":"Zheng J, Wang S, Xia L, Sun Z, Chan KM, Bernards R, Qin W, Chen J, Xia Q, Jin H (2025) Hepatocellular carcinoma: signaling pathways and therapeutic advances. Signal Transduct Target Ther 10:35. https:\/\/doi.org\/10.1038\/s41392-024-02075-w","journal-title":"Signal Transduct Target Ther"},{"key":"12760_CR3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s40364-025-00774-2","volume":"13","author":"X Guo","year":"2025","unstructured":"Guo X, Zhao Z, Zhu L, Liu S, Zhou L, Wu F, Fang S, Chen M, Zheng L, Ji J (2025) The evolving landscape of biomarkers for systemic therapy in advanced hepatocellular carcinoma. Biomark Res 13:60. https:\/\/doi.org\/10.1186\/s40364-025-00774-2","journal-title":"Biomark Res"},{"key":"12760_CR4","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378\u2013390. https:\/\/doi.org\/10.1056\/NEJMoa0708857","journal-title":"N Engl J Med"},{"key":"12760_CR5","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1007\/s10620-012-2136-1","volume":"57","author":"B Xie","year":"2012","unstructured":"Xie B, Wang DH, Spechler SJ (2012) Sorafenib for treatment of hepatocellular carcinoma: a systematic review. Dig Dis Sci 57:1122\u20131129. https:\/\/doi.org\/10.1007\/s10620-012-2136-1","journal-title":"Dig Dis Sci"},{"key":"12760_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41392-020-0187-x","volume":"5","author":"W Tang","year":"2020","unstructured":"Tang W, Chen Z, Zhang W, Cheng Y, Zhang B, Wu F et al (2020) The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther 5:87. https:\/\/doi.org\/10.1038\/s41392-020-0187-x","journal-title":"Signal Transduct Target Ther"},{"key":"12760_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.envres.2023.115683","volume":"227","author":"YE Alqurashi","year":"2023","unstructured":"Alqurashi YE, Al-Hetty H, Ramaiah P, Fazaa AH, Jalil AT, Alsaikhan F et al (2023) Harnessing function of EMT in hepatocellular carcinoma: from biological view to nanotechnological standpoint. Environ Res 227:115683. https:\/\/doi.org\/10.1016\/j.envres.2023.115683","journal-title":"Environ Res"},{"key":"12760_CR8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1146\/annurev-pathmechdis-051222-122423","volume":"19","author":"R Fontana","year":"2024","unstructured":"Fontana R, Mestre-Farrera A, Yang J (2024) Update on epithelial-mesenchymal plasticity in cancer progression. Annu Rev Pathol 19:133\u2013156. https:\/\/doi.org\/10.1146\/annurev-pathmechdis-051222-122423","journal-title":"Annu Rev Pathol"},{"key":"12760_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13123026","volume":"13","author":"H Moon","year":"2021","unstructured":"Moon H, Ro SW (2021) MAPK\/ERK signaling pathway in hepatocellular carcinoma. Cancers (Basel) 13:3026. https:\/\/doi.org\/10.3390\/cancers13123026","journal-title":"Cancers (Basel)"},{"key":"12760_CR10","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.7150\/ijms.51256","volume":"18","author":"Y Ma","year":"2021","unstructured":"Ma Y, Xu R, Liu X, Zhang Y, Song L, Cai S et al (2021) LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells. Int J Med Sci 18:1456\u20131464. https:\/\/doi.org\/10.7150\/ijms.51256","journal-title":"Int J Med Sci"},{"key":"12760_CR11","doi-asserted-by":"publisher","first-page":"15311","DOI":"10.1007\/s00432-023-05272-2","volume":"149","author":"H Shi","year":"2023","unstructured":"Shi H, Zou Y, Zhong W, Li Z, Wang X, Yin Y, Li D, Liu Y, Li M (2023) Complex roles of Hippo-YAP\/TAZ signaling in hepatocellular carcinoma. J Cancer Res Clin Oncol 149:15311\u201315322. https:\/\/doi.org\/10.1007\/s00432-023-05272-2","journal-title":"J Cancer Res Clin Oncol"},{"key":"12760_CR12","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114351","volume":"13","author":"R Gao","year":"2021","unstructured":"Gao R, Kalathur RKR, Coto-Llerena M, Ercan C, Buechel D, Shuang S et al (2021) YAP\/TAZ and ATF4 drive resistance to sorafenib in hepatocellular carcinoma by preventing ferroptosis. EMBO Mol Med 13:EMMM202114351. https:\/\/doi.org\/10.15252\/emmm.202114351","journal-title":"EMBO Mol Med"},{"key":"12760_CR13","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1093\/hmg\/ddq125","volume":"19","author":"SP Brooks","year":"2010","unstructured":"Brooks SP, Coccia M, Tang HR, Kanuga N, Machesky LM, Bailly M, Cheetham ME, Hardcastle AJ (2010) The Nance-Horan syndrome protein encodes a functional WAVE homology domain (WHD) and is important for co-ordinating actin remodelling and maintaining cell morphology. Hum Mol Genet 19:2421\u20132432. https:\/\/doi.org\/10.1093\/hmg\/ddq125","journal-title":"Hum Mol Genet"},{"key":"12760_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25916-6","volume":"12","author":"AL Law","year":"2021","unstructured":"Law AL, Jalal S, Pallett T, Mosis F, Guni A, Brayford S et al (2021) Nance-Horan syndrome-like 1 protein negatively regulates Scar\/WAVE-Arp2\/3 activity and inhibits lamellipodia stability and cell migration. Nat Commun 12:5687. https:\/\/doi.org\/10.1038\/s41467-021-25916-6","journal-title":"Nat Commun"},{"key":"12760_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55647-3","volume":"16","author":"NM Novikov","year":"2025","unstructured":"Novikov NM, Gao J, Fokin AI, Rocques N, Chiappetta G, Rysenkova KD et al (2025) NHSL3 controls single and collective cell migration through two distinct mechanisms. Nat Commun 16:205. https:\/\/doi.org\/10.1038\/s41467-024-55647-3","journal-title":"Nat Commun"},{"key":"12760_CR16","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3892\/ol.2020.11588","volume":"20","author":"Y Xu","year":"2020","unstructured":"Xu Y, Sun C, Han B, Xi Y, Zhang M, Yang J, Chen Z (2020) High KIAA1522 expression predicts a poor prognosis in patients with hepatocellular carcinoma. Oncol Lett 20:509\u2013516. https:\/\/doi.org\/10.3892\/ol.2020.11588","journal-title":"Oncol Lett"},{"key":"12760_CR17","doi-asserted-by":"publisher","first-page":"5657","DOI":"10.2147\/OTT.S251157","volume":"13","author":"S Jiang","year":"2020","unstructured":"Jiang S, Zhang Y, Li Q, Qiu L, Bian B (2020) KIAA1522 promotes the progression of hepatocellular carcinoma via the activation of the Wnt\/\u03b2-catenin signaling pathway. Onco Targets Ther 13:5657\u20135668. https:\/\/doi.org\/10.2147\/OTT.S251157","journal-title":"Onco Targets Ther"},{"key":"12760_CR18","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.18632\/aging.202306","volume":"13","author":"B Hu","year":"2020","unstructured":"Hu B, Yang XB, Yang X, Sang XT (2020) LncRNA CYTOR affects the proliferation, cell cycle and apoptosis of hepatocellular carcinoma cells by regulating the miR-125b-5p\/KIAA1522 axis. Aging (Albany NY) 13:2626\u20132639. https:\/\/doi.org\/10.18632\/aging.202306","journal-title":"Aging (Albany NY)"},{"key":"12760_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2022.154276","volume":"241","author":"C Liu","year":"2023","unstructured":"Liu C, Ren C, Guo L, Yang C, Yu Q (2023) Exosome-mediated circTTLL5 transfer promotes hepatocellular carcinoma malignant progression through miR-136-5p\/KIAA1522 axis. Pathol Res Pract 241:154276. https:\/\/doi.org\/10.1016\/j.prp.2022.154276","journal-title":"Pathol Res Pract"},{"key":"12760_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70710","volume":"16","author":"X Li","year":"2026","unstructured":"Li X, Hu S, Shi H, Bian P, Wang Z, Sun J (2026) Super-enhancer-driven KIAA1522 upregulation suppresses ferroptosis in hepatocellular carcinoma. Clin Transl Med 16:e70710. https:\/\/doi.org\/10.1002\/ctm2.70710","journal-title":"Clin Transl Med"},{"key":"12760_CR21","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.2147\/OTT.S142610","volume":"10","author":"ZH Xie","year":"2017","unstructured":"Xie ZH, Yu J, Shang L, Zhu YQ, Hao JJ, Cai Y, Xu X, Zhang Y, Wang MR (2017) KIAA1522 overexpression promotes tumorigenicity and metastasis of esophageal cancer cells through potentiating the ERK activity. Onco Targets Ther 10:3743\u20133754. https:\/\/doi.org\/10.2147\/OTT.S142610","journal-title":"Onco Targets Ther"},{"key":"12760_CR22","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s13046-020-01684-x","volume":"39","author":"B Wang","year":"2020","unstructured":"Wang B, Jing T, Jin W, Chen J, Wu C, Wang M, Liu Y (2020) KIAA1522 potentiates TNF\u03b1-NF\u03baB signaling to antagonize platinum-based chemotherapy in lung adenocarcinoma. J Exp Clin Cancer Res 39:170. https:\/\/doi.org\/10.1186\/s13046-020-01684-x","journal-title":"J Exp Clin Cancer Res"},{"key":"12760_CR23","first-page":"3858","volume":"42","author":"H Nakabayashi","year":"1982","unstructured":"Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J (1982) Growth of human hepatoma cell lines with differentiated functions in chemically defined medium. Cancer Res 42:3858\u20133863","journal-title":"Cancer Res"},{"key":"12760_CR24","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/282615a0","volume":"282","author":"DP Aden","year":"1979","unstructured":"Aden DP, Fogel A, Plotkin S, Damjanov I, Knowles BB (1979) Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature 282:615\u2013616. https:\/\/doi.org\/10.1038\/282615a0","journal-title":"Nature"},{"key":"12760_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0124633","volume":"10","author":"M Stemmer","year":"2015","unstructured":"Stemmer M, Thumberger T, Del Sol Keyer M, Wittbrodt J, Mateo JL (2015) CCTop: an intuitive, flexible and reliable CRISPR\/Cas9 target prediction tool. PLoS ONE 10:e0124633. https:\/\/doi.org\/10.1371\/journal.pone.0124633","journal-title":"PLoS ONE"},{"key":"12760_CR26","doi-asserted-by":"publisher","first-page":"W242","DOI":"10.1093\/nar\/gky354","volume":"46","author":"JP Concordet","year":"2018","unstructured":"Concordet JP, Haeussler M (2018) CRISPOR: intuitive guide selection for CRISPR\/Cas9 genome editing experiments and screens. Nucleic Acids Res 46:W242\u2013W245. https:\/\/doi.org\/10.1093\/nar\/gky354","journal-title":"Nucleic Acids Res"},{"key":"12760_CR27","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.3437","volume":"34","author":"JG Doench","year":"2016","unstructured":"Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF et al (2016) Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol 34:184\u2013191. https:\/\/doi.org\/10.1038\/nbt.3437","journal-title":"Nat Biotechnol"},{"key":"12760_CR28","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.3390\/ijms27072959","volume":"27","author":"G Y\u0131ld\u0131z","year":"2026","unstructured":"Y\u0131ld\u0131z G, Karabulut S, Dincer T, Toraman B (2026) Loss of LLGL1 elevates EGFR\/RAS\/MAPK signaling and remodels EMT markers in Huh-7 hepatocellular carcinoma cells. Int J Mol Sci 27:2959. https:\/\/doi.org\/10.3390\/ijms27072959","journal-title":"Int J Mol Sci"},{"key":"12760_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/biot.201900397","volume":"15","author":"S Han","year":"2020","unstructured":"Han S, Cui Y, Helbing DL (2020) Inactivation of horseradish peroxidase by acid for sequential chemiluminescent western blot. Biotechnol J 15:e1900397. https:\/\/doi.org\/10.1002\/biot.201900397","journal-title":"Biotechnol J"},{"key":"12760_CR30","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.2147\/OTT.S289324","volume":"14","author":"W Zhou","year":"2021","unstructured":"Zhou W, Lou W, Chen J, Ding B, Chen B, Xie H, Zhou L, Zheng S, Jiang D (2021) AG-1024 sensitizes sorafenib-resistant hepatocellular carcinoma cells to sorafenib via enhancing G1\/S arrest. Onco Targets Ther 14:1049\u20131059. https:\/\/doi.org\/10.2147\/OTT.S289324","journal-title":"Onco Targets Ther"},{"key":"12760_CR31","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/s41419-018-0926-x","volume":"9","author":"LL Niu","year":"2018","unstructured":"Niu LL, Cheng CL, Li MY, Yang SL, Hu BG, Chong CCN, Chan SL, Ren J, Chen GG, Lai PBS (2018) ID1-induced p16\/IL6 axis activation contributes to the resistant of hepatocellular carcinoma cells to sorafenib. Cell Death Dis 9:852. https:\/\/doi.org\/10.1038\/s41419-018-0926-x","journal-title":"Cell Death Dis"},{"key":"12760_CR32","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1091\/mbc.E17-03-0134","volume":"28","author":"C De Pascalis","year":"2017","unstructured":"De Pascalis C, Etienne-Manneville S (2017) Single and collective cell migration: the mechanics of adhesions. Mol Biol Cell 28:1833\u20131846. https:\/\/doi.org\/10.1091\/mbc.E17-03-0134","journal-title":"Mol Biol Cell"},{"key":"12760_CR33","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1158\/1535-7163.MCT-10-0544","volume":"10","author":"T Nagai","year":"2011","unstructured":"Nagai T, Arao T, Furuta K, Sakai K, Kudo K, Kaneda H et al (2011) Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma. Mol Cancer Ther 10:169\u2013177. https:\/\/doi.org\/10.1158\/1535-7163.MCT-10-0544","journal-title":"Mol Cancer Ther"},{"key":"12760_CR34","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41580-020-0237-9","volume":"21","author":"J Yang","year":"2020","unstructured":"Yang J, Antin P, Berx G, Blanpain C, Brabletz T, Bronner M et al (2020) Guidelines and definitions for research on epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 21:341\u2013352. https:\/\/doi.org\/10.1038\/s41580-020-0237-9","journal-title":"Nat Rev Mol Cell Biol"},{"key":"12760_CR35","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1038\/s43018-024-00839-5","volume":"5","author":"KK Youssef","year":"2024","unstructured":"Youssef KK, Narwade N, Arcas A, Marquez-Galera A, Jimenez-Castano R, Lopez-Blau C et al (2024) Two distinct epithelial-to-mesenchymal transition programs control invasion and inflammation in segregated tumor cell populations. Nat Cancer 5:1660\u20131680. https:\/\/doi.org\/10.1038\/s43018-024-00839-5","journal-title":"Nat Cancer"},{"key":"12760_CR36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s43018-022-00473-z","volume":"4","author":"S Piccolo","year":"2023","unstructured":"Piccolo S, Panciera T, Contessotto P, Cordenonsi M (2023) YAP\/TAZ as master regulators in cancer: modulation, function and therapeutic approaches. Nat Cancer 4:9\u201326. https:\/\/doi.org\/10.1038\/s43018-022-00473-z","journal-title":"Nat Cancer"},{"key":"12760_CR37","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s13402-021-00595-z","volume":"44","author":"T Sun","year":"2021","unstructured":"Sun T, Mao W, Peng H, Wang Q, Jiao L (2021) YAP promotes sorafenib resistance in hepatocellular carcinoma by upregulating survivin. Cell Oncol (Dordr) 44:689\u2013699. https:\/\/doi.org\/10.1007\/s13402-021-00595-z","journal-title":"Cell Oncol (Dordr)"},{"key":"12760_CR38","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.cell.2013.08.021","volume":"154","author":"FA Ran","year":"2013","unstructured":"Ran FA, Hsu PD, Lin CY, Gootenberg JS, Konermann S, Trevino AE et al (2013) Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154:1380\u20131389. https:\/\/doi.org\/10.1016\/j.cell.2013.08.021","journal-title":"Cell"},{"key":"12760_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s44321-023-00008-8","author":"L Torella","year":"2024","unstructured":"Torella L, Klermund J, Bilbao-Arribas M, Tamayo I, Andrieux G, Chmielewski KO, Vales A, Olag\u00fce C, Moreno-Luqui D, Raimondi I, Abad A, Torrens-Baile J, Salido E, Huarte M, Hernaez M, Boerries M, Cathomen T, Zabaleta N, Gonzalez-Aseguinolaza G (2024) Efficient and safe therapeutic use of paired Cas9-nickases for primary hyperoxaluria type 1. EMBO Mol Med. https:\/\/doi.org\/10.1038\/s44321-023-00008-8","journal-title":"EMBO Mol Med"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12760-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12760-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12760-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T12:26:07Z","timestamp":1789734367000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12760-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12760"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12760-4","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"assertion":[{"value":"8 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics apporval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1591"}}